A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2017; you can also visit the original URL.
The file type is
ASEAN Heart Journal
The approval of the new target specifi c oral anticoagulants provides clinicians with alternatives to warfarin. This review focuses on dabigatran, a direct thrombin inhibitor and rivaroxavan, a direct factor Xa inhibitor. These new oral anticoagulants have favourable pharmacological properties that overcome many of the problems associated with warfarin use. Their effi cacy and safety have also been shown in large Phase III randomized studies in VTE prevention in major orthopedic surgery,doi:10.7603/s40602-014-0002-4 fatcat:tl5zj3jcujdtphm6tqkuya2aqa